These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26342296)

  • 21. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
    Kay LJ; Griffiths ID;
    Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study.
    Brennan-Bourdon LM; De la Cruz-Mosso U; Reyes-Castillo Z; Martínez-Bonilla GE; Ramírez-Dueñas MG; Islas-Carbajal MC; Rincón-Sánchez AR; Salazar-Páramo M; Muñoz-Valle JF
    Immunopharmacol Immunotoxicol; 2015 Apr; 37(2):207-13. PubMed ID: 25721154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
    Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
    Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
    Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
    Kamata Y; Minota S
    Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
    Reumatizam; 2008; 55(1):22-5. PubMed ID: 19024266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France.
    Fagnani F; Pham T; Claudepierre P; Berenbaum F; De Chalus T; Saadoun C; Joubert JM; Fautrel B
    J Med Econ; 2016 Aug; 19(8):812-21. PubMed ID: 27065315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
    Heather EM; Payne K; Harrison M; Symmons DP
    Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial.
    Pease C; Pope JE; Thorne C; Haraoui BP; Truong D; Bombardier C; Widdifield J; Psaradellis E; Sampalis JS; Bonner A
    J Rheumatol; 2010 Dec; 37(12):2469-74. PubMed ID: 20843910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.
    Fautrel B; Pham T; Mouterde G; Le Loët X; Goupille P; Guillemin F; Ravaud P; Cantagrel A; Dougados M; Puéchal X; Sibilia J; Soubrier M; Mariette X; Combe B; ;
    Joint Bone Spine; 2007 Dec; 74(6):627-37. PubMed ID: 18037319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
    Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
    Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome and safety of TNFα antagonist therapy in 475 consecutive outpatients (with rheumatoid arthritis or spondyloarthropathies) treated by a single physician according to their eligibility for clinical trials.
    Berthelot JM; Benoist-Gérard S; le Goff B; Muller-Chevalet F; Maugars Y
    Joint Bone Spine; 2010 Dec; 77(6):564-9. PubMed ID: 20621538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.
    Marshall NJ; Wilson G; Lapworth K; Kay LJ
    Rheumatology (Oxford); 2004 Aug; 43(8):1034-8. PubMed ID: 15150436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
    Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
    Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern?
    Jerram S; Butt S; Gadsby K; Deighton C
    Rheumatology (Oxford); 2008 Feb; 47(2):180-2. PubMed ID: 18160419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.